LJI Professor Sujan Shresta Wins New Funding to Investigate Dengue and Chikungunya Virus Vaccines

Media Type
Article
Publish or Event Date
Research Institution
La Jolla Institute for Immunology
Short Title
LJI Professor Sujan Shresta Wins New Funding
Content Coordinator
Content Manager

CAHNR Researcher Wins $3.8 Million NIH Grant to Develop Leptospirosis Vaccine

New Mouse Models Offer Valuable Window into COVID-19 Infection

NIH Awards UAMS $3.7 Million in Quest for More Effective Tuberculosis Vaccine

Houston Methodist Prepares for Next Pandemic as Part of National NIH-Funded Consortium

Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Media Type
Article
Publish or Event Date
Research Institution
Gylden Pharma
Short Title
Emergex T Cell-Priming Vaccine Candidate
Content Coordinator
Content Manager

How Doxycycline for STI Prevention Affects the Gut Microbiome

UGA Partners with FDA to Test U.S. Dairy Supplies for Avian Influenza

Among People with HIV, Mpox Vaccine Protects Well

News Briefs and Worth Repeating

Funding News Edition:
See more articles in this edition

Note an Addendum to NIAID’s Financial Management Plan for FY 2025

For competing investigator-initiated R01 applications submitted by new and early-stage investigators, NIAID will fund new awards at their approved funding level (without any percentage reduction). At the outset of fiscal year (FY) 2025, we had not identified this subset of applications as excluded from our approach of funding competing investigator-initiated awards at 97 percent of approved funding level.

Read our FY 2025 Financial Management Plan for additional details. Refer also to Information for New Investigators.

HHS ASPR Posts FAQs on DURC/PEPP Policy

We noted, in our June 5, 2024 news brief “New Government-Wide Policy for Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential in May 2025,” that a new Policy for Oversight of Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential would expand the scope of research requiring additional scrutiny and strengthen government coordination with institutions to ensure robust review and oversight.

Our preparation for the May 6, 2025 implementation date is ongoing. Until then, HHS’s Administration for Strategic Preparedness and Response is posting (and answering) frequently asked questions (FAQs) about the policy from the research community. Find them at Frequently Asked Questions: United States Government Policy for Oversight of Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential.

The government has made ASPRBIO@hhs.gov available for questions and feedback from stakeholders on interpreting or implementing the Policy. Feedback will be used for policy evaluation purposes and may result in FAQs. Not all emails to this email address may receive a direct response.

New Scientific Integrity Policies Focus on Public Trust

In recent months, HHS and NIH have each announced new policies for scientific integrity. Read NIH’s announcement at Final Scientific Integrity Policy of the National Institutes of Health. Note that this is in addition to NIH policies on Research Integrity, which champion trustworthy and professional conduct, methodology, and results reporting within NIH-supported research.

Per the announcement, the new Scientific Integrity Policy is meant to ensure that 1) scientific findings are objective, credible, and readily available to the public, and 2) the development and implementation of policies and programs is transparent, accountable, and evidence-based. Practically speaking, the policy is meant to govern NIH and its staff, rather than the extramural community.

Contact Us

Email us at deaweb@niaid.nih.gov for help navigating NIAID’s grant and contract policies and procedures.